Investigating genetic and molecular profiles of pediatric brain tumors in China

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on pediatric patients diagnosed with medulloblastomas and other malignant central nervous system tumors. It aims to collect genetic and cellular profiles through advanced techniques such as whole genome sequencing, RNA sequencing, and single-cell sequencing. Patients will be monitored post-surgery for clinical outcomes and quality of life, with follow-up assessments including MRI scans to evaluate tumor progression. The study seeks to correlate genetic characteristics with clinical prognosis to identify potential therapeutic targets.

Why it matters

Who can join: the full rules

Inclusion Criteria:

\- Children and adolescents aged between 0-18 years old, diagnosed with medulloblastoma or other malignant central nervous system tumors including glioma, ependymoma, germ cell tumors,tuberous sclerosis, neuronal and neuronoglial tumors, choroid plexus tumors, atypical teratoid/rhabdoid tumors, ependymoblastoma, and medulloepithelioma;

Patients must be eligible for and receive tumor resection;

Histological examination by institutional neuro-pathological evaluation must confirmed the diagnosis of brain malignancies;

Participants consent with joining the current study and comply with follow-up visits;

The patients must have no previous radiotherapy or chemotherapy other than corticosteroids.

Exclusion Criteria:

\- Patients with major perioperative complications which lead to significant and sudden deterioration;

Patients with major systemic illness (e.g., serious infection or significant cardiac, pulmonary, hepatic, or other organ dysfunction) which might compromise the patient's ability to tolerate standard treatment or would likely interfere with overall prognosis;

Patients with major adverse events or sudden deterioration irrelevant to the current study;

Quality of tumor tissue sample did not meet the criterion for genetic sequencing and laboratory investigations;

Patients who refuse to participate in the study or who request dropping out from the study

Where it's running

• Beijing Tiantan Hosiptal
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Principal investigator: Tao Jiang, MD — Beijing Tiantan Hospital
• Study coordinator: Tao Jiang, MD
• Email: doctorjiangtt@163.com
• Phone: +8613501306106

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• B7-H3 CAR T cells for recurrent brain tumors in kids and young adults

  This early-phase trial tests a personalized CAR T-cell therapy called B7-H3 CAR T for children and young adults with recurrent or progressive brain tumors.

  Recruiting at 2 sites Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT07390539

• Pharmacoscopy-guided treatment for refractory brain tumors

  This trial tests whether personalized drug testing on a patient’s tumor cells can guide treatment choices for adults with hard-to-treat brain cancers like glioblastoma.

  Recruiting Phase 2 University of Zurich · Basel, Basel-Landschaft and 2 other locations · NCT06804655

• Identifying biomarkers to predict cognitive decline after radiation therapy for brain tumors

  This study is trying to find specific markers in blood and spinal fluid from young patients with brain tumors to see if they can predict problems with thinking and memory after radiation treatment.

  Recruiting Tata Memorial Centre · Mumbai, Maharashtra · NCT06779487

• Testing PLX038 for brain and spinal cord tumors with MYC or MYCN amplifications

  This study is testing a new treatment called PLX038 for adults with brain and spinal cord tumors that have specific gene changes to see if it helps improve their condition.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06161519

• Observational assessment of treatment outcomes for patients with primary brain tumors

  This study looks at how well treatments work for people with rare primary brain tumors using new classification guidelines to see if they help doctors group patients better.

  Recruiting at 42 sites European Organisation for Research and Treatment of Cancer - EORTC · Innsbruck and 41 other locations · NCT05259605

• Locoregional immunotherapy using CAR T cells for pediatric brain tumors

  This study is testing a new treatment using specially modified immune cells to see if it can help children and young adults with certain types of brain tumors feel better.

  Recruiting Phase 1 Seattle Children's Hospital · Seattle, Washington · NCT04185038

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.